Advertisement

Medical Oncology

, Volume 27, Supplement 1, pp 25–42 | Cite as

Advances in treatment for relapses and refractory multiple myeloma

  • Tiffany Richards
  • Donna WeberEmail author
Original Paper

Abstract

Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma. These advances are largely due to thalidomide-, lenalidomide-, and bortezomib-based combinations that have improved response rates, not only in patients with untreated disease, but also in those with relapsed and/or refractory myeloma, in some cases producing response rates up to 85%. Eventually, however, nearly all patients relapse, emphasizing a continuing role for the introduction of investigational agents that overcome drug resistance. This article will review the current role for thalidomide, lenalidomide, and bortezomib-based combinations, as well as some preliminary findings for promising investigational agents currently in clinical trials for patients with relapsed and/or refractory disease.

Keywords

Multiple myeloma Relapsed Refractory Treatment advances 

Notes

Conflict of interest statements

Tiffany Richards, A.N.P: Speaker’s Bureau/Honoraria Celgene and Millennium; Advisory Board: Celgene, Millennium, Kyphon. Donna M Weber, MD: Research Support: Celgene, Millennium, Merck; Honoraria for speaking (none within 2 years): Celgene, Millennium; Advisory Board (unpaid consultant): Merck. The authors received an honorarium for their participation in this supplement.

References

  1. 1.
    Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2):86–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968;31(1):1–10.PubMedGoogle Scholar
  3. 3.
    Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80(4):887–90.PubMedGoogle Scholar
  4. 4.
    Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells. 1995;13(Suppl 2):118–21.PubMedGoogle Scholar
  5. 5.
    Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Anderson K, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M, Ghobrial I, Knight R, Esseltine D, Richardson P. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. J Clin Oncol. 2009;27(15 s).Google Scholar
  8. 8.
    Kumar S, Flinn IW, Noga SJ, et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center evolution study. ASH Ann Meet Abstr. 2008;112(11):93.Google Scholar
  9. 9.
    Harousseau JL, Mathiot C, Attal M, et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. ASH Ann Meet Abstr. 2007;110(11):450.Google Scholar
  10. 10.
    Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British J Haematol. 2005;129(6):776–83.CrossRefGoogle Scholar
  11. 11.
    Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASH Ann Meet Abstr. 2007;110(11):74.Google Scholar
  12. 12.
    Reeder CB, Reece DE, Fonseca R, et al. A phase II trial of myeloma induction therapy with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D): improved response over historical lenalidomide-dexamethasone controls. ASH Ann Meet Abstr. 2007;110(11):3601.Google Scholar
  13. 13.
    Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Ann Meet Abstr. 2007;110(11):77.Google Scholar
  14. 14.
    Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America [see comment]. N Engl J Med. 2007;357(21):2133–42.CrossRefPubMedGoogle Scholar
  15. 15.
    Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [see comment]. N Engl J Med. 2007;357(21):2123–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009. blood-2008-12-193458.Google Scholar
  17. 17.
    Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2006;21(1):151–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Reece DE, Masih-Khan E, Khan A, et al. Phase I–II trial of oral cyclophosphamide, prednisone and lenalidomide (revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):1723.Google Scholar
  19. 19.
    Reece DE, Rodriguez GP, Chen C, et al. Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26(29):4777–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113(18):4137–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Palumbo A, Falco P, Sanpaolo G, et al. Combination of lenalidomide, melphalan, prednisone and thalidomide (RMPT) in relapsed/refractory multiple myeloma: results of a multicenter phase II clinical trial. ASH Ann Meet Abstr. 2008;112(11):868.Google Scholar
  22. 22.
    Kropff M, Liebisch P, Wand H, et al. Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma. ASH Ann Meet Abst. 2007;110(11):3599.Google Scholar
  23. 23.
    Colado E, Mateos M-V, Moreno M-J, et al. VAMP/ThaCyDex: Velcade(R) (Bortezomib), adriamycin, melphalan and prednisone alternating with thalidomide, cyclophosphamide and dexamethasone as a salvage regimen in relapsed multiple myeloma patients. ASH Ann Meet Abstr. 2008;112(11):3694.Google Scholar
  24. 24.
    Davies FE, Wu P, Jenner M, Srikanth M, Saso R, Morgan GJ. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD). Haematologica. 2007;92(8):1149–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.CrossRefPubMedGoogle Scholar
  26. 26.
    Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed//refractory multiple myeloma. Leukemia. 2004;18(4):856–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Reece DE, Leitch HA, Atkins H, et al. Treatment of relapsed and refractory myeloma. Leukemia Lymphoma. 2008;49(8):1470–85.CrossRefPubMedGoogle Scholar
  28. 28.
    Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. British J Haematol. 2003;121(5):768–77.CrossRefGoogle Scholar
  29. 29.
    Roussou M, Anagnostopoulos A, Kastritis E, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments. Leukemia Lymphoma. 2007;48(4):754–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Kyriakou C, Thomson K, D’Sa S, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British J Haematol. 2005;129(6):763–70.CrossRefGoogle Scholar
  31. 31.
    Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol. 2006;76(4):273–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Weber DM GM, Delasalle K, et al. Thalidomide alone or with dexamethasone for multiple myeloma. Blood 1999;94(604a).Google Scholar
  33. 33.
    Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943–50.PubMedGoogle Scholar
  34. 34.
    Zangari MBB, Jacobson J, et al. VTD regimen comprising velcade (V) + thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood 2003;102(11).Google Scholar
  35. 35.
    Lee C-K, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003;21(14):2732–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. British J Haematol. 2008;143(2):191–200.CrossRefGoogle Scholar
  37. 37.
    Morris T, Kettle P, Drake M, et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British J Haematol. 2008;143(3):349–54.CrossRefGoogle Scholar
  38. 38.
    Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc. 2006;81(7):889–95.CrossRefPubMedGoogle Scholar
  39. 39.
    Muller GW, Chen R, Huang S-Y, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-[alpha] production. Bioorg Med Chem Lett. 1999;9(11):1625–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009. blood-2008-12-196238.Google Scholar
  42. 42.
    Schey S, Morgan GJ, Ramasamy K, et al. CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma. ASH Ann Meet Abstr. 2008;112(11):3707.Google Scholar
  43. 43.
    Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy (HDCT). Blood 2001;775a.Google Scholar
  44. 44.
    Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23(11):2147–52.Google Scholar
  45. 45.
    Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008;112(12):4445–51.CrossRefPubMedGoogle Scholar
  47. 47.
    Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. ASH Ann Meet Abstr. 2006;108(11):3547.Google Scholar
  48. 48.
    Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47(12):1466–75.CrossRefPubMedGoogle Scholar
  49. 49.
    Avet-Loiseau H, Soulier J, Fermand J, Facon T, Attal M, Harousseau J, Belhadj K, Hulin C, Garderet L, Dorvaux V, Moreau P. Impact of chromosomal abnormalities del (13), t(4:14), and del (17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2008;112(11).Google Scholar
  50. 50.
    Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Prac Res Clin Haematol. 2007;20(4):625–35.CrossRefGoogle Scholar
  51. 51.
    Avet-Loiseau H. Genetic implications in myeloma: prognostic implications. Clin Lymphoma myeloma 2009;9(S2).Google Scholar
  52. 52.
    Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA Italian multiple myeloma network. J Clin Oncol. 2007;25(28):4459–65.CrossRefPubMedGoogle Scholar
  53. 53.
    Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33–47.CrossRefPubMedGoogle Scholar
  54. 54.
    Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [see comment]. N Engl J Med. 2003;348(26):2609–17.CrossRefPubMedGoogle Scholar
  56. 56.
    Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British J Haematol. 2004;127(2):165–72.CrossRefGoogle Scholar
  57. 57.
    Jagannath S, Barlogie B, Berenson JR, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537–40.PubMedGoogle Scholar
  58. 58.
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]. N Engl J Med. 2005;352(24):2487–98.CrossRefPubMedGoogle Scholar
  59. 59.
    Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071–6.PubMedGoogle Scholar
  61. 61.
    Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009;144(6):887–94.CrossRefPubMedGoogle Scholar
  62. 62.
    Berenson J, Yang H, Vescio R, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol. 2008;87(8):623–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Terpos E, Delimpasi S, Anargyrou K, et al. The combination of bortezomib, doxorubicin, and dexamethasone (PAD) is an effective regimen for high risk, newly diagnosed, patients with multiple myeloma, reduces bone resorption and normalizes angiopoietin-1 to angiopoietin-2 ratio. ASH Ann Meet Abstr. 2007;110(11):3596.Google Scholar
  64. 64.
    Pineda-Roman M, Zangari M, van Rhee F, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008;22(7):1419–27.CrossRefPubMedGoogle Scholar
  65. 65.
    Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008;19(6):1160–5.CrossRefPubMedGoogle Scholar
  66. 66.
    Di Raimondo F, Romano A, Gorgone A, et al. Salvage therapy with intravenous liposomal adryamicin (A), bortezomib (B), cyclophosphamide (C), and dexamethasone (D) (ABCD) in previously treated myeloma patients. ASH Ann Meet Abstr. 2008;112(11):2779.Google Scholar
  67. 67.
    Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784–90.CrossRefPubMedGoogle Scholar
  68. 68.
    San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906–17.CrossRefPubMedGoogle Scholar
  69. 69.
    Richardson P, Jagannath S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. ASH Ann Meet Abstr. 2008;112(11):1742.Google Scholar
  70. 70.
    Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9(3):1136–44.PubMedGoogle Scholar
  71. 71.
    Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058–65.CrossRefPubMedGoogle Scholar
  72. 72.
    Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892–901.CrossRefPubMedGoogle Scholar
  73. 73.
    Chanan-Khan A, Miller KC, Musial L, et al. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia Lymphoma. 2009;50(7):1096–101.CrossRefPubMedGoogle Scholar
  74. 74.
    Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol. 2006;17(12):1766–71.CrossRefPubMedGoogle Scholar
  75. 75.
    Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British J Haematol. 2008;141(6):814–9.CrossRefGoogle Scholar
  76. 76.
    Offidani M, Bringhen S, Corvatta L, et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol. 2007;78(4):297–302.CrossRefPubMedGoogle Scholar
  77. 77.
    Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol. 1994;53(4):207–12.PubMedCrossRefGoogle Scholar
  78. 78.
    Jagannath S, Barlogie B, Berenson J, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005;103(6):1195–200.CrossRefPubMedGoogle Scholar
  79. 79.
    San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22(4):842–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73(2):98–103.CrossRefPubMedGoogle Scholar
  81. 81.
    Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. British J Haematol. 2003;122(1):160–1.CrossRefGoogle Scholar
  82. 82.
    Celegene. Celegene Package Insert.Google Scholar
  83. 83.
    Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113–20.CrossRefPubMedGoogle Scholar
  84. 84.
    Palumbo A, Bringhen S, Rossi D, et al. A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. J Clin Oncol. 2009;27(15 s):437.Google Scholar
  85. 85.
    Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British J Haematol. 2008;143(2):222–9.CrossRefGoogle Scholar
  86. 86.
    Barlogie B, Attal M, Crowley J, Harousseau J. Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) total therapy (TT) trials. J Clin Oncol 2009;27(15 s):438.Google Scholar
  87. 87.
    Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–90.CrossRefPubMedGoogle Scholar
  88. 88.
    Vij R, Wang M, Orlowski R, et al. Initial results of PX-171–004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). ASH Ann Meet Abstr. 2008;112(11):865.Google Scholar
  89. 89.
    Vij R, Wang M, Orlowski R, et al. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: an efficacy update. J Clin Oncol. 2009;27:443.Google Scholar
  90. 90.
    Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA. 2004;101(2):540–5.CrossRefPubMedGoogle Scholar
  91. 91.
    Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia Lymphoma. 2008;49(3):502–7.CrossRefPubMedGoogle Scholar
  92. 92.
    Weber D, Badros AZ, Jagannath S, et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. ASH Ann Meet Abstr. 2008;112(11):871.Google Scholar
  93. 93.
    Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107(10):4053–62.CrossRefPubMedGoogle Scholar
  94. 94.
    Jakubowiak A, Richardson P, Zimmerman TM, et al. Phase I results of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). ASH Ann Meet Abstr. 2008;112(11):3691.Google Scholar
  95. 95.
    Richardson P, Wolf J, Jakubowiak A, et al. Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. ASH Ann Meet Abstr. 2008;112(11):870.Google Scholar
  96. 96.
    Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol. 2009;145(4):481–90.CrossRefPubMedGoogle Scholar
  97. 97.
    Voorhees PM, Manges R, Somlo G, Lentzsch S, Jagannath S, Sonneveld P, Frank R, Zweegman S, Wijermans P, Thomas S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2009;27(15 s):440.Google Scholar
  98. 98.
    Rossi J-F, Manges RF, Sutherland HJ, et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):867.Google Scholar
  99. 99.
    Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007;110(7):2641–9.CrossRefPubMedGoogle Scholar
  100. 100.
    Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006;107(3):1092–100.CrossRefPubMedGoogle Scholar
  101. 101.
    Richardson P, Chanan-Khan A, Lonial S, Krishnan A, Carroll M, Alsina M, Albitar M, Berman D, Kaplita S, Anderson K. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I/II study. J Clin Oncol. 2009;27(15 s):434.Google Scholar
  102. 102.
    Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed//refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22(12):2247–56.CrossRefPubMedGoogle Scholar
  103. 103.
    Offidani M, Corvatta L, Marconi M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica. 2006;91(1):133–6.PubMedGoogle Scholar
  104. 104.
    Jagannath S, Vij R, Stewart AK, et al. Initial results of PX-171–003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). ASH Ann Meet Abstr. 2008;112(11):864.Google Scholar
  105. 105.
    Niesvizky R, Bensinger W, Vallone A, Gutierrez L, Kunkel. PX-171-006: Phase 1b multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone in relapsed and refractory multiple myeloma: preliminary results. J Clin Oncol. 2009;27(15 s):444.Google Scholar
  106. 106.
    Siegel D, Weber D, Mitsiades CS, et al. A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):3705.Google Scholar
  107. 107.
    Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (Pom/dex) is highly effective therapy in relapsed multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):866.Google Scholar
  108. 108.
    Siegel Dd, Sezer O, San Miguel JF, et al. A phase IB, multicenter, open-label, dose-escalation study of Oral panobinostat (LBH589) and I. V. bortezomib in patients with relapsed multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):2781.Google Scholar
  109. 109.
    Badros A, Philip S, Niesvizky R, et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). ASH Ann Meet Abstr. 2007;110(11):1168.Google Scholar
  110. 110.
    Hofmeister C, Richardson P, Zimmerman T, Spear M, Palladino M, Longenecker A, Cropp G, Lloyd G, Hannah A, Anderson K. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009;27(15 s):435.Google Scholar
  111. 111.
    Harrison SJ, Quach H, Yuen K, et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. ASH Ann Meet Abstr. 2008;112(11):3698.Google Scholar
  112. 112.
    Ghobrial IM, Munshi N, Schlossman R, et al. Phase I trial of CCI-779 (Temsirolimus) and weekly bortezomib in relapsed and/or refractory multiple myeloma. ASH Ann Meet Abstr. 2008;112(11):3696.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.MD Anderson Cancer CenterHoustonUSA

Personalised recommendations